Cargando…

Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients

Most patients with multiple myeloma (MM) undergoing autologous hematopoietic stem cell transplantation (autoHCT) eventually relapse, perhaps due to the presence of clonal plasma cells (CPC) in the autograft. We conducted a retrospective analysis to evaluate the impact of CPC in the autograft on the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pasvolsky, Oren, Milton, Denái R., Rauf, Mikael, Ghanem, Sassine, Masood, Adeel, Mohamedi, Ali H., Tanner, Mark R., Bashir, Qaiser, Srour, Samer, Saini, Neeraj, Lin, Paul, Ramdial, Jeremy, Nieto, Yago, Tang, Guilin, Lee, Hans C., Patel, Krina K., Kebriaei, Partow, Thomas, Sheeba K., Weber, Donna M., Orlowski, Robert Z., Rezvani, Katy, Champlin, Richard, Shpall, Elizabeth J., Lin, Pei, Qazilbash, Muzaffar H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10156676/ https://www.ncbi.nlm.nih.gov/pubmed/37137874 http://dx.doi.org/10.1038/s41408-023-00842-6

Ejemplares similares

P1279: OUTCOMES OF AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH MULTIPLE MYELOMA WITH TWO OR MORE HIGH-RISK CYTOGENETIC ABNORMALITIES
por: Pasvolsky, Oren, et al.
Publicado: (2023)

Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant
por: Nieto, Yago, et al.
Publicado: (2023)

P1299: OUTCOMES OF YOUNG ADULTS (AGED ≤40 YEARS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANT
por: Pasvolsky, Oren, et al.
Publicado: (2023)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

P1303: DARATUMUMAB-BASED MAINTENANCE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AFTER SALVAGE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Pasvolsky, Oren, et al.
Publicado: (2023)

P1376: LENALIDOMIDE–BASED MAINTENANCE AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK MULTIPLE MYELOMA
por: Pasvolsky, O., et al.
Publicado: (2022)

Allogeneic Hematopoietic Cell Transplantation for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
por: Bashir, Qaiser, et al.
Publicado: (2022)

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities
por: Popat, Uday R., et al.
Publicado: (2023)

A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study
por: Popat, Uday R., et al.
Publicado: (2022)

Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide
por: Mehta, Rohtesh S., et al.
Publicado: (2021)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

P1270: MYELOABLATIVE FRACTIONATED BUSULFAN-BASED CONDITIONING REGIMEN IN PATIENTS WITH AML AND MDS: RESULTS OF A RANDOMIZED CLINICAL TRIAL COMPARING 2 FRACTIONATION SCHEDULES
por: Popat, Uday R., et al.
Publicado: (2023)

Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis
por: Nieto, Yago, et al.
Publicado: (2021)

Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead
por: Pasvolsky, Oren, et al.
Publicado: (2023)

A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin’s lymphomas
por: Hosing, Chitra, et al.
Publicado: (2010)

Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type
por: Mehta, Rohtesh S., et al.
Publicado: (2023)

Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan
por: Nieto, Yago, et al.
Publicado: (2017)

Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future
por: Sanchez-Petitto, Gabriela, et al.
Publicado: (2023)

Impact of renal impairment on light chain amyloidosis outcomes after autologous hematopoietic stem cell transplantation
por: Srour, Samer A., et al.
Publicado: (2020)

Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma
por: Patel, Krina K., et al.
Publicado: (2022)

Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies
por: Singh, Harjeet, et al.
Publicado: (2022)

Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement
por: Akin, Serkan, et al.
Publicado: (2022)

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood
por: Huls, M. Helen, et al.
Publicado: (2013)

Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions
por: Greenbaum, Uri, et al.
Publicado: (2020)

A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation
por: Andersson, Borje S., et al.
Publicado: (2022)

ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV
por: Strati, Paolo, et al.
Publicado: (2023)

Fludarabine with pharmacokinetically-guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
por: Andersson, Borje S., et al.
Publicado: (2016)

Mesenchymal Stem Cell Therapy in the Treatment of Acute and Chronic Graft Versus Host Disease
por: Kebriaei, Partow, et al.
Publicado: (2011)

Autologous transplant and second malignancies in MM
por: Pasvolsky, Oren, et al.
Publicado: (2023)

Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation
por: Saliba, Rima M., et al.
Publicado: (2020)

Steroid-Refractory Acute GVHD: Predictors and Outcomes
por: Westin, Jason R., et al.
Publicado: (2011)

Outcomes of Hospital-Associated Covid-19 in Hematopoietic Cell Transplant (HCT) Recipients: A Single Center Experience
por: Srinivasan, Krithika, et al.
Publicado: (2022)

Allogeneic and Autologous Hematopoietic Transplants Can be Safely Performed after COVID-19 Infections
por: Ramdial, Jeremy L., et al.
Publicado: (2021)

Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation
por: Konopleva, Marina, et al.
Publicado: (2015)

Long-Term Follow-up Outcomes of Patients That Underwent Allogeneic or Autologous Hematopoietic Transplant Shortly after a COVID-19 Infection
por: Marinos, Alejandro, et al.
Publicado: (2023)

2122. The Impact of HHV-6 DNAemia on hematopoietic cell transplant (HCT) recipients at high risk for CMV reactivation in the era of Letermovir
por: Srinivasan, Krithia, et al.
Publicado: (2022)

Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?
por: Wallis, Whitney D, et al.
Publicado: (2017)

Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports
por: Milgrom, Sarah A., et al.
Publicado: (2016)

2121. The Impact of Donor CMV Serostatus on Outcomes of CMV Infections in the Era of Letermovir
por: Aramburo, Oscar Morado, et al.
Publicado: (2022)

1995. Duration of letermovir primary prophylaxis in hematopoietic cell transplant recipients at high risk for cytomegalovirus infections and impact on outcomes
por: Febres-Aldana, Anthony J, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_raekjba86sch510uvte79kpv2q